Angela Hu - Feb 10, 2023 Form 3 Insider Report for XBiotech Inc. (XBIT)

Role: Principle Financial Officer
Signature: /s/ Angela Hu
Stock symbol: XBIT
Transactions as of: Feb 10, 2023
Transactions value $: $0
Form type: 3
Date filed: 2/23/2023, 01:51 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	XBIT	Common Stock						25.5K	Feb 10, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XBIT	Employee Stock Option (right to buy)							Feb 10, 2023	Common Stock	4.5K	$19.00	Direct	F1
holding	XBIT	Employee Stock Option (right to buy)							Feb 10, 2023	Common Stock	5K	$5.26	Direct	F2
holding	XBIT	Employee Stock Option (right to buy)							Feb 10, 2023	Common Stock	10K	$10.36	Direct	F3
holding	XBIT	Employee Stock Option (right to buy)							Feb 10, 2023	Common Stock	10K	$12.67	Direct	F4
holding	XBIT	Employee Stock Option (right to buy)							Feb 10, 2023	Common Stock	30K	$3.84	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On April 1, 2015 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in four years commencing as of April 1, 2016, with an expiry of ten years from the Grant Date.
F2	On January 4, 2019 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of January 4, 2020, with an expiry of ten years from the Grant Date.
F3	On November 6, 2019 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of November 6, 2020, with an expiry of ten years from the Grant Date.
F4	On November 19, 2021 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of November 19, 2022, with an expiry of ten years from the Grant Date.
F5	On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date.